Outcomes of Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

BACKGROUND: Philadelphia chromosome-positive (Ph+) advanced leukemias including acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML-MBP) have poor outcomes. Venetoclax (VEN) has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in pre-clinical studies. How...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Acta Haematol
Auteurs principaux: Maiti, Abhishek, Franquiz, Miguel, Ravandi, Farhad, Cortes, Jorge E., Jabbour, Elias J., Sasaki, Koji, Marx, Kayleigh, Daver, Naval G., Kadia, Tapan M., Konopleva, Marina Y., Masarova, Lucia, Borthakur, Gautam, DiNardo, Courtney D., Naqvi, Kiran, Pierce, Sherry, Kantarjian, Hagop M., Short, Nicholas J.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839068/
https://ncbi.nlm.nih.gov/pubmed/32289808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000506346
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires